相关临床试验
73
19 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1911
进行中（未招募）
1
1.4%
已完成
29
39.7%
尚未招募
18
24.7%
招募中
17
23.3%
暂停
1
1.4%
终止
3
4.1%
Unknown
3
4.1%
撤回
1
1.4%
暂无批准数据
- Western Australia's Cook Labor Government and The Hospital Research Foundation Group have awarded $775,000 to 15 precision medicine research projects across the state. - Four researchers received Tier One grants of $125,000 over two years, while 11 projects received Tier Two grants of $25,000 over one year. - Funded work targets cancer, dementia, cardiovascular disease, stroke and mental health, including a precision nasal spray for Alzheimer's disease. - The competitive grant round marks the third major collaboration between The Hospital Research Foundation Group and the FHRI Fund in the past 12 months.
- ProGenis Pharmaceuticals received funding from MTPConnect's TTRA program to advance PGP-011, a small RNA drug targeting insulin resistance in type 2 diabetes patients. - The experimental treatment works by blocking production of a specific cellular enzyme that interferes with insulin production, addressing a root cause of the disease. - Research indicates PGP-011 reduces target expression and lowers glucose levels more effectively than dapagliflozin, a current standard treatment. - The funding announcement was made at the BIO International Convention in Boston, highlighting Australia's growing medical technology sector.
